CRABP1

Summary

CRABP1 (cellular retinoic acid binding protein 1, HGNC:2338) is a protein-coding gene on chromosome 15q25.1, encoding Cellular retinoic acid-binding protein 1 (P29762). Cytosolic CRABPs may regulate the access of retinoic acid to the nuclear retinoic acid receptors.

This gene encodes a specific binding protein for a vitamin A family member and is thought to play an important role in retinoic acid-mediated differentiation and proliferation processes. It is structurally similar to the cellular retinol-binding proteins, but binds only retinoic acid at specific sites within the nucleus, which may contribute to vitamin A-directed differentiation in epithelial tissue.

Source: NCBI Gene 1381 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 16 total
• Druggable target: yes
• MANE Select transcript: NM_004378

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2338
Approved symbol	CRABP1
Name	cellular retinoic acid binding protein 1
Location	15q25.1
Locus type	gene with protein product
Status	Approved
Aliases	CRABP, CRABP-I, CRABPI
Ensembl gene	ENSG00000166426
Ensembl biotype	protein_coding
OMIM	180230
Entrez	1381

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000299529, ENST00000406419, ENST00000560753, ENST00000923226, ENST00000923227, ENST00000923228, ENST00000923229, ENST00000923230, ENST00000923231

RefSeq mRNA: 1 — MANE Select: NM_004378 NM_004378

CCDS: CCDS10301

Canonical transcript exons

ENST00000299529 — 4 exons

Exon	Start	End
ENSE00001102851	78341043	78341221
ENSE00001159810	78340353	78340498
ENSE00001818207	78347927	78348225
ENSE00003508772	78343499	78343612

Expression profiles

Bgee: expression breadth ubiquitous, 202 present calls, max score 96.98.

FANTOM5 (CAGE): breadth broad, TPM avg 61.0604 / max 3765.2742, expressed in 514 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
147898	61.0134	514
147902	0.0470	26

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left lobe of thyroid gland	UBERON:0001120	96.98	gold quality
right lobe of thyroid gland	UBERON:0001119	96.63	gold quality
thyroid gland	UBERON:0002046	96.43	gold quality
caudate nucleus	UBERON:0001873	93.75	gold quality
nucleus accumbens	UBERON:0001882	93.32	gold quality
middle frontal gyrus	UBERON:0002702	91.80	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.76	gold quality
superior vestibular nucleus	UBERON:0007227	91.70	gold quality
spleen	UBERON:0002106	91.42	gold quality
putamen	UBERON:0001874	90.40	gold quality
trigeminal ganglion	UBERON:0001675	89.95	gold quality
hypothalamus	UBERON:0001898	89.24	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.99	gold quality
ventral tegmental area	UBERON:0002691	84.93	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	83.76	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	83.52	gold quality
spinal cord	UBERON:0002240	83.17	gold quality
prefrontal cortex	UBERON:0000451	82.28	gold quality
amygdala	UBERON:0001876	81.84	gold quality
midbrain	UBERON:0001891	81.50	gold quality
substantia nigra	UBERON:0002038	81.05	gold quality
right frontal lobe	UBERON:0002810	80.73	gold quality
embryo	UBERON:0000922	79.78	gold quality
Brodmann (1909) area 10	UBERON:0013541	79.58	gold quality
oocyte	CL:0000023	79.30	gold quality
cingulate cortex	UBERON:0003027	78.63	gold quality
anterior cingulate cortex	UBERON:0009835	78.55	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	78.39	gold quality
Brodmann (1909) area 9	UBERON:0013540	78.06	gold quality
medulla oblongata	UBERON:0001896	78.04	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-MTAB-8894	yes	15750.14
E-GEOD-137537	yes	7879.72
E-HCAD-56	yes	4650.72
E-MTAB-7316	yes	4205.63
E-GEOD-124472	yes	3130.60
E-MTAB-10485	yes	3002.41
E-HCAD-5	yes	2857.70
E-GEOD-93593	yes	2107.43
E-MTAB-7407	yes	1750.11
E-GEOD-98556	yes	1381.99
E-CURD-6	yes	27.66
E-MTAB-9388	yes	13.62
E-MTAB-10042	yes	8.11
E-MTAB-6108	no	4005.94
E-ANND-3	no	1.73

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, EP300, HES1, HOXB1, JUN, NR2C1, RARA, TP63, ZBTB16

miRNA regulators (miRDB)

8 targeting CRABP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-5088-3P	98.29	66.63	1310
HSA-MIR-6783-5P	97.67	67.21	1528
HSA-MIR-324-5P	95.68	65.20	560
HSA-MIR-1973	93.96	64.98	81

Literature-anchored findings (GeneRIF, showing 28)

• Loss of cellular retinoic acid binding protein 1 function due to hypermethylation of its promoter leads to pathogenesis of papillary thyroid carcinoma (PMID:12640681)
• CSF of Moyamoya Disease [MMD] patients reveals high CRABP-I expression suggesting that the elevation of CRABP-I in CSF may be a candidate for pathogenesis of MMD (PMID:14605320)
• CRABP I plays an important role not only in mediating the retinoid effects, but also in modulating the radiation sensitivity of tumour cells after combined retinoic acid radiation treatment. (PMID:14713576)
• increased CYP26-mediated catabolism of retinoic by CRABP-I transfection might decrease the amount of retinoic acid that is accessible to the nuclear receptors (PMID:15281009)
• Decreases in the CRABP1 (cellular retinoic acid binding protein 1) and TFF3 (trefoil factor 3) expression levels identified these as candidate molecular biomarkers for papillary thyroid carcinoma. (PMID:15515157)
• Real-time RT-PCR analysis disclosed a significant lack of CRABP-I expression in four renal cell carcinoma cell lines (PMID:16254461)
• Hypermethylation was subsequently identified for three of four analyzed genes, ADAMTS1 (85%), CRABP1 (90%), and NR3C1 (35%). (PMID:17167179)
• Frequent methylation-associated silencing of CRABP1 is associated with esophageal squamous-cell carcinoma (PMID:17438526)
• DNA hypermethylation of tumour suppressor genes seems to play an important role in ovarian carcinogenesis and HOXA9, HOXB5, SCGB3A1, and CRABP1 are identified as novel hypermethylated target genes in this tumour type (PMID:17623056)
• As epidermal basal keratinocyte proliferation is stimulated by paracrine growth factors secreted by ATRA activated suprabasal keratinocytes, our results indicate that CRABPI overexpression in suprabasal keratinocytes enhances ATRA. (PMID:17727842)
• supports an active role for PLZF and RARalpha-PLZF in leukemogenesis, identifies up-regulation of CRABPI (PMID:18000064)
• The authors identified several dysregulated genes and proteins, but only the cellular retinoic acid binding protein 1 (CRABP1) was up-regulated exclusively in cells expressing an increased Abeta42/Abeta40 ratio. (PMID:19087254)
• reduced expression of CRABP1 has a potential as a prognostic marker for serous adenocarcinoma which is the most frequent histological ovarian tumor type and also for clear cell carcinoma that often exhibits chemo-resistance. (PMID:20571827)
• Results describe the mRNA expression of CRABP1, RERG, and GRP in pituitary adenomas. (PMID:21270509)
• Factors involved in the retinoid pathway, in particular upregulation of CRBP, CRABP1 and CRABP2, also showed differential expression in tumors with different histological subtypes (PMID:24269351)
• the first evidence of pro-tumorigenic and pro-metastatic activity of CRABP1 in mesenchymal and neuroendocrine tumors. (PMID:24626200)
• we demonstrated significant changes in CRABP1 and CRABP2 expression in non-small cell lung cancer samples (PMID:25034531)
• miR-93/miR-106b/miR-375-CIC-CRABP1 is a novel key regulatory axis in prostate cancer progression (PMID:26124181)
• CRABP1 expression is maintained in ER- and triple-negative breast tumors, and that elevated levels of CRABP1 is a significant indicator of high tumor grade, Ki67 immunoreactivity, and poor prognosis. (PMID:26142905)
• p75NTR and CRABP1 modulate the effect of fenretinide on neuroblastoma cells (PMID:26843908)
• Holo-CRABPs had higher affinity for CYP26B1 than free atRA, but both apo-CRABPs(CRABP-I and CRABP-II ) inhibited the formation of 4-OH-RA by CYP26B1. (PMID:27416800)
• We conclude that the underexpression of CRABP1 and the overexpression of LCN2 may be useful diagnostic biomarkers in thyroid tumours with questionable malignity, and the overexpression of LCN2 and C1QL1 may be useful for prognostic purposes. (PMID:29321030)
• Regulation of Hepatitis C Virus Infection by Cellular Retinoic Acid Binding Proteins through the Modulation of Lipid Droplet Abundance. (PMID:30728260)
• These are supported by the fact that CRABP1 gene knockout (KO) mice exhibit multiple phenotypes including hippocampal NSC expansion and spontaneous cardiac hypertrophy. This indicates that more potential processes/signaling pathways involving atRA-CRABP1 may exist, which remain to be identified. (PMID:31344789)
• Cellular Retinoic-Acid Binding Protein 2 in Solid Tumor. (PMID:32013828)
• Sonic Hedgehog-Gli1 Signaling and Cellular Retinoic Acid Binding Protein 1 Gene Regulation in Motor Neuron Differentiation and Diseases. (PMID:32527063)
• CRABP1 and CRABP2 Protein Levels Correlate with Each Other but Do Not Correlate with Sensitivity of Breast Cancer Cells to Retinoic Acid. (PMID:33832420)
• Expression of cellular retinoic acid binding protein 1 predicts peritoneal recurrence of gastric cancer. (PMID:35417033)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	crabp1b	ENSDARG00000035904
danio_rerio	crabp1a	ENSDARG00000045926
mus_musculus	Crabp1	ENSMUSG00000032291
rattus_norvegicus	Crabp1	ENSRNOG00000023633
drosophila_melanogaster	fabp	FBGN0037913
caenorhabditis_elegans		WBGENE00002259
caenorhabditis_elegans		WBGENE00002260

Paralogs (15): RBP2 (ENSG00000114113), RBP1 (ENSG00000114115), FABP3 (ENSG00000121769), RBP5 (ENSG00000139194), CRABP2 (ENSG00000143320), FABP2 (ENSG00000145384), PMP2 (ENSG00000147588), RBP7 (ENSG00000162444), FABP1 (ENSG00000163586), FABP7 (ENSG00000164434), FABP5 (ENSG00000164687), FABP6 (ENSG00000170231), FABP4 (ENSG00000170323), FABP12 (ENSG00000197416), FABP9 (ENSG00000205186)

Protein

Protein identifiers

Cellular retinoic acid-binding protein 1 — P29762 (reviewed: P29762)

Alternative names: Cellular retinoic acid-binding protein I

All UniProt accessions (3): B5MCB5, P29762, F1T0F7

UniProt curated annotations — full annotation on UniProt →

Function. Cytosolic CRABPs may regulate the access of retinoic acid to the nuclear retinoic acid receptors.

Subcellular location. Cytoplasm.

Domain organisation. Forms a beta-barrel structure that accommodates hydrophobic ligands in its interior.

Similarity. Belongs to the calycin superfamily. Fatty-acid binding protein (FABP) family.

RefSeq proteins (1): NP_004369* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000463	Fatty_acid-bd	Domain
IPR000566	Lipocln_cytosolic_FA-bd_dom	Domain
IPR012674	Calycin	Homologous_superfamily
IPR031259	ILBP	Family

Pfam: PF00061

UniProt features (5 total): sequence conflict 2, chain 1, short sequence motif 1, binding site 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
7A9Y	X-RAY DIFFRACTION	1.64
7A9Z	X-RAY DIFFRACTION	2.41

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P29762-F1	96.10	0.96

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 132–134

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-5365859	RA biosynthesis pathway

MSigDB gene sets: 194 (showing top): ATF_B, GCANCTGNY_MYOD_Q6, BECKER_TAMOXIFEN_RESISTANCE_UP, SP3_Q3, MODULE_45, GGGTGGRR_PAX4_03, MODULE_404, LA_MEN1_TARGETS, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, GOBP_ORGANIC_ACID_TRANSPORT, CREB_Q4, MODULE_66, MODULE_118, PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP, MCLACHLAN_DENTAL_CARIES_DN

GO Biological Process (2): signal transduction (GO:0007165), fatty acid transport (GO:0015908)

GO Molecular Function (7): retinoic acid binding (GO:0001972), retinoid binding (GO:0005501), fatty acid binding (GO:0005504), retinal binding (GO:0016918), retinol binding (GO:0019841), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (3): nucleus (GO:0005634), cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by Retinoic Acid	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
retinoid binding	3
monocarboxylic acid binding	2
vitamin binding	2
binding	2
cellular anatomical structure	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
lipid transport	1
monocarboxylic acid transport	1
isoprenoid binding	1
lipid binding	1
alcohol binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1312 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CRABP1	RARA	P10276	790
CRABP1	CACNA1G	O43497	765
CRABP1	RARB	P10826	762
CRABP1	NEUROG1	Q92886	735
CRABP1	RARS1	P54136	720
CRABP1	CYP26C1	Q6V0L0	701
CRABP1	CYP26A1	O43174	678
CRABP1	RBP3	P10745	674
CRABP1	HOXA1	P49639	670
CRABP1	RUNX3	Q13761	664
CRABP1	ZBTB16	Q05516	629
CRABP1	STRA6	Q9BX79	620
CRABP1	RARG	P13631	616
CRABP1	SOCS1	O15524	608
CRABP1	MLH1	P40692	607

IntAct

34 interactions, top by confidence:

A	B	Type	Score
CETN1	SFI1	psi-mi:“MI:0914”(association)	0.640
TSPO	CRABP1	psi-mi:“MI:0915”(physical association)	0.590
TH	CRABP1	psi-mi:“MI:0915”(physical association)	0.560
NHERF1	CRABP1	psi-mi:“MI:0915”(physical association)	0.560
SYNGAP1	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
CRABP1	CFTR	psi-mi:“MI:0915”(physical association)	0.510
CFTR	CRABP1	psi-mi:“MI:0915”(physical association)	0.510
	CRABP1	psi-mi:“MI:0915”(physical association)	0.510
CRABP1		psi-mi:“MI:0915”(physical association)	0.510
TRA2A	CRABP1	psi-mi:“MI:0915”(physical association)	0.370
PRNP	WDR91	psi-mi:“MI:0914”(association)	0.350
ANK2	IGKV2-40	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350
CACNA1C	IGLL5	psi-mi:“MI:0914”(association)	0.350
CACNA1C	CACNB4	psi-mi:“MI:0914”(association)	0.350
SYNGAP1	POTEF	psi-mi:“MI:0914”(association)	0.350
CACNA1C	SNRPGP15	psi-mi:“MI:0914”(association)	0.350
HCN1	POTEF	psi-mi:“MI:0914”(association)	0.350
SYNGAP1	IGLON5	psi-mi:“MI:0914”(association)	0.350
	SHTN1	psi-mi:“MI:0914”(association)	0.350
VCP	SHTN1	psi-mi:“MI:0914”(association)	0.350
VCP	FAM171A2	psi-mi:“MI:0914”(association)	0.350
CRABP1	TH	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (15): CRABP1 (Affinity Capture-MS), CRABP1 (Affinity Capture-MS), CRABP1 (Two-hybrid), TH (Two-hybrid), CRABP1 (Affinity Capture-MS), CRABP1 (Affinity Capture-MS), CRABP1 (Affinity Capture-MS), CRABP1 (PCA), CORO1B (Cross-Linking-MS (XL-MS)), CRABP1 (Cross-Linking-MS (XL-MS)), CRABP1 (Affinity Capture-MS), CRABP1 (Affinity Capture-MS), CRABP1 (Affinity Capture-MS), TRA2A (Two-hybrid), CRABP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0K9RL25, A0A0U1WZ18, B9N1F9, B9SQI7, E0CSI1, I3SPW2, O15305, O42386, O80526, O88600, O97555, O97556, P21856, P22935, P29373, P29762, P31150, P34932, P40220, P50396, P50398, P50568, P51673, P60028, P62964, P62965, P62966, Q2QNG7, Q2QZ86, Q2TFN9, Q3C1F4, Q42785, Q5PXY7, Q5R2J5, Q5R5C9, Q5RDM4, Q5ZID6, Q60HD6, Q61316, Q6AY30

Diamond homologs: A0A0K0MJ13, A0A0K0MJN3, A6NFH5, A6YLM6, A8MUU1, B7SUM8, C4N147, O01812, O01814, O02323, O02324, O02772, O08716, O13008, O15540, O42386, O45035, O76821, O97788, P02689, P02690, P02691, P02694, P02696, P04117, P05413, P06768, P07148, P07483, P09455, P0C6G6, P10790, P11404, P12710, P15090, P22935, P24526, P29373, P29498, P29762

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

16 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	14
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

583 predictions. Top by Δscore:

Variant	Effect	Δscore
15:78340492:GCAC:G	donor_gain	1.0000
15:78340497:GG:G	donor_gain	1.0000
15:78340498:GG:G	donor_gain	1.0000
15:78340499:G:GA	donor_loss	1.0000
15:78340499:G:GG	donor_gain	1.0000
15:78340500:T:A	donor_loss	1.0000
15:78343498:GA:G	acceptor_gain	1.0000
15:78341212:C:T	donor_gain	0.9900
15:78341220:GG:G	donor_gain	0.9900
15:78341221:GG:G	donor_gain	0.9900
15:78347922:TGCA:T	acceptor_loss	0.9900
15:78347924:CAGAC:C	acceptor_loss	0.9900
15:78347925:A:T	acceptor_loss	0.9900
15:78347926:G:GT	acceptor_loss	0.9900
15:78347926:GAC:G	acceptor_gain	0.9900
15:78340496:TGG:T	donor_gain	0.9800
15:78340497:GGG:G	donor_gain	0.9800
15:78340561:G:GT	donor_gain	0.9800
15:78341192:G:GT	donor_gain	0.9800
15:78343495:GCAG:G	acceptor_loss	0.9800
15:78343497:A:AG	acceptor_gain	0.9800
15:78343497:AGAGT:A	acceptor_loss	0.9800
15:78343498:G:GG	acceptor_gain	0.9800
15:78343498:G:T	acceptor_loss	0.9800
15:78343608:TCCTG:T	donor_loss	0.9800
15:78343609:CCTG:C	donor_loss	0.9800
15:78343610:CTG:C	donor_loss	0.9800
15:78343611:TG:T	donor_loss	0.9800
15:78343612:GG:G	donor_loss	0.9800
15:78343613:G:A	donor_loss	0.9800

AlphaMissense

904 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:78341070:C:A	A33D	0.999
15:78343583:C:A	R112S	0.999
15:78347953:C:G	C130W	0.999
15:78340450:T:A	W8R	0.998
15:78340450:T:C	W8R	0.998
15:78340452:G:C	W8C	0.998
15:78340452:G:T	W8C	0.998
15:78341061:G:T	R30M	0.998
15:78341211:G:C	R80P	0.998
15:78343584:G:C	R112P	0.998
15:78343605:T:C	L119P	0.998
15:78343611:T:C	L121P	0.998
15:78347952:G:A	C130Y	0.998
15:78340487:T:C	L20P	0.997
15:78341061:G:C	R30T	0.997
15:78341062:G:C	R30S	0.997
15:78341062:G:T	R30S	0.997
15:78341186:T:C	F72L	0.997
15:78341188:T:A	F72L	0.997
15:78341188:T:G	F72L	0.997
15:78341210:C:A	R80S	0.997
15:78343577:T:A	W110R	0.997
15:78343577:T:C	W110R	0.997
15:78347951:T:C	C130R	0.997
15:78340451:G:C	W8S	0.996
15:78340474:T:C	F16L	0.996
15:78340476:C:A	F16L	0.996
15:78340476:C:G	F16L	0.996
15:78341169:T:C	F66S	0.996
15:78341204:G:C	D78H	0.996

dbSNP variants (sampled 300 via entrez): RS1000533445 (15:78340050 A>G), RS1000576819 (15:78347880 G>C), RS1000650487 (15:78348165 T>C), RS1000681553 (15:78348354 G>C), RS1000811062 (15:78342169 A>C,G), RS1001241956 (15:78342433 C>T), RS1001343942 (15:78343398 G>A), RS1001710251 (15:78343109 C>T), RS1002003440 (15:78346997 T>TG), RS1002269996 (15:78341700 G>A), RS1002343722 (15:78342091 G>A,C), RS1002578735 (15:78341390 C>T), RS1003274909 (15:78340218 C>A,T), RS1003347022 (15:78340537 C>A,T), RS1003686154 (15:78348380 G>A,C)

Disease associations

OMIM: gene MIM:180230 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003476_6	Eyebrow thickness	1.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2079 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Fatty acid-binding proteins

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, increases methylation	8
Tretinoin	decreases response to substance, affects cotreatment, decreases expression, increases expression	5
trichostatin A	affects cotreatment, increases expression	3
Tetrachlorodibenzodioxin	decreases expression, affects cotreatment	3
bisphenol A	decreases expression	2
sodium arsenite	decreases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
Decitabine	affects expression, affects methylation	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Cadmium	decreases expression, increases abundance, increases expression	2
methylmercuric chloride	decreases expression	1
propionaldehyde	increases expression	1
terbufos	increases methylation	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	affects cotreatment, decreases expression	1
benzo(e)pyrene	decreases methylation, increases methylation	1
aflatoxin B2	decreases methylation, increases methylation	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
pentanal	increases expression	1
tebuconazole	decreases expression	1
CGP 52608	affects binding, increases reaction	1
dorsomorphin	affects cotreatment, increases expression, decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
Arsenic Trioxide	decreases reaction, affects binding	1
Alitretinoin	decreases response to substance	1
Panobinostat	affects cotreatment, increases expression	1
Aldehydes	increases expression	1
Atrazine	increases expression	1
Calcitriol	decreases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL664298	Binding	Inhibition of [3H]-retinoic acid binding to Cellular retinoic acid-binding protein (CRABP) from chick embryo skin	Inhibition of papilloma formation by analogues of 7,8-dihydroretinoic acid. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.